Vivatlac in Irritable Bowel Syndrome II (ViIBS2)

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
Multi-center,randomized, double-blind, placebo-controlled, 36 weeks trial investigating the effects of a nine-strain synbiotic (Vivatlac Synbiotikum) in IBS patients
Epistemonikos ID: 8576aacb9738f7ac47d3c6498a22b795faf005ee
First added on: Nov 20, 2025